Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 901–999 of 999
Evaluation of CAR-T Cell Cytotoxicity against a Prostate Carcinoma Model
Валиуллина, А. Х., Zmievskaya, E., Rakhmatullina, A. R., Zuravleva, M. N., Garanina, E. E., Рифкатовна, М. Р., Petukhov, A., Rizvanov, A. A., & Bulatov, E. (2022) · Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učënye zapiski Kazanskogo universiteta. Seriâ Estestvennye nauki/Učenye zapiski Kazanskogo gosudarstvennogo universiteta. Seriâ Estestvennye nauki · doi:10.26907/2542-064x.2022.2.212-230
Impaired tumor death receptor signaling drives resistance to CAR T cell therapyPreprint
Singh, N., Shestova, O. E., Ravikumar, P., Hayer, K. E., Hong, S. J., Orlando, E. J., Mueller, K. T., Good, C. R., Berger, S. L., Shalem, O., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/627562 · Cited by 1
Sun, H., He, S., Meng, L., Wang, Y., Zhang, H., Liu, Y., Wang, J., Tao, M., Barta, S. K., Dulaimi, E., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3294754 · Cited by 1
CBFA2T3-GLIS2 oncogenic fusion is sufficient for leukemic transformationPreprint
Le, Q., Hadland, B., Smith, J. L., Leonti, A. R., Huang, B. J., Ries, R. E., Hylkema, T., Castro, S., Tang, T. T., Nourigat, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-757279/v1 · Cited by 1
Cellular therapies: Hematology and beyond
Vasu, S. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.03.001 · Cited by 1
Peters, T., Mühlgrabner, V., Cárdenas, R. M.-H. V., Platzer, R., Göhring, J., Salzer, B., Plach, A., Höhrhan, M., Perez, I. D., Gonçalves, V. D. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.16.532775 · Cited by 1
Koula, G., Yakati, V., Rachamalla, H. K., Bhamidipati, K., Kathirvel, M., Banerjee, R., & Puvvada, N. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4500354 · Cited by 1
Quantifying target antigen-dependent CAR T-cell performance against AMLPreprint
Shah, S., Mueller, J., Vogel, E., Raatz, M., Boettcher, S., Traulsen, A., Manz, M. G., & Altrock, P. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.16.628628 · Cited by 1
Total body irradiation primes CD19-directed CAR T cells against large B-cell lymphomaPreprint
Alhomoud, M., Foley, M., Sugita, M., Fein, J. A., Yamshon, S., Martinez, L. M., Rejeski, K., Astorkia, M., Betel, D., Brentjens, R. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643462 · Cited by 2
Snyder, A. J., Shasha, C., Ho, T., Garrison, S. M., Wilhelm, A. R., Kluesner, M. G., Ortiz, S., Nutt, W. S., Bingham, E., Bhise, S. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648245 · Cited by 1
Immunopathology and Immunotherapy of Hodgkin Lymphoma
Ebadi, M., Zeng, Y., Gkotzamanidou, M. A., & Rezaei, N. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_7
Information-dense analysis for information-dense understanding
Ivica, N. A., Kaur, M., Hu, G., & Chen, J. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.21
“CAR-T therapies may benefit from using PBMCs as the source of T cells based on recent observations that administration of a defined ratio of CD4:CD8 CAR-T cells results in superior therapy efficacy (13).”
BackgroundNovel Cell Therapies and Manipulations: Ready for Prime-Time?
(2017) · Cambridge University Press eBooks · doi:10.1017/9781316335727.063
Adoptiver Immuntransfer und CAR-T-Zellen bei malignen Erkrankungen
Echchannaoui, H., Dietrich, K., & Theobald, M. (2017) · Der Onkologe · doi:10.1007/s00761-017-0274-y
“Auch mit den zwei αCD19 CAR-T-Zell-Produkten JCAR017 und JCAR014 wurden in klinischen Studien hohe und dauerhafte Ansprechraten bei Patienten mit r/r-NHL erzielt [30].”
BackgroundSimon, S., Charpentier, M., Anegón, I., & Labarrière, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0094
The curative potential of chimeric antigen receptor T-cell therapy for B-cell malignancies
Koduri, M. P. (2017) · OpenBU (Boston University)
Britten, C. M., Johnson, L. A., Quintás‐Cardama, A., Sheppard, N. C., & Hoos, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_42
Cell‐Based Therapies for Canine Cancer
Mason, N. J., & Panjwani, M. K. (2018) · Wiley eBooks · doi:10.1002/9781118684535.ch18
Adoptiver Immuntransfer und CAR-T-Zellen bei malignen Erkrankungen
Echchannaoui, H., Dietrich, K., & Theobald, M. (2018) · Wiener klinisches Magazin · doi:10.1007/s00740-018-0219-0
“Auch mit den zwei αCD19 CAR-T-Zell-Produkten JCAR017 und JCAR014 wurden in klinischen Studien hohe und dauerhafte Ansprechraten bei Patienten mit r/r-NHL erzielt [30].”
BackgroundImmune Gene Therapy and the International Conference on Lymphocyte Engineering (ICLE 2018)
Barzel, A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.29069.aba
Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018
Abutalib, S. A., & Gill, S. I. (2018) · Advances and controversies in hematopoietic transplantation and cell therapy · doi:10.1007/978-3-319-54368-0_2
Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challenges
Batlevi, Y., & Sauter, C. S. (2018) · Advances and controversies in hematopoietic transplantation and cell therapy · doi:10.1007/978-3-319-54368-0_6
Fry, T. J., & Jacoby, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00008-6
T-Zellen mit chimärem Antigenrezeptor (CAR) bei akuter B‑Zell-Leukämie
Hudecek, M. (2019) · best practice onkologie · doi:10.1007/s11654-018-0117-3
Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
Htut, M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-0492-z
L’émergence des traitements par cellules CAR-T dans les lymphomes
Salles, G. A., Sesques, P., Ferrant, E., Safar, V., Ghesquières, H., & Bachy, E. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(19)30047-5 · Cited by 1
Gestion des toxicités des lymphocytes T exprimant un récepteur à l’antigène chimérique (CAR-T cells)
Bourgeois, A. L. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(19)30049-9 · Cited by 1
Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma
Chae, H., & Yoon, D. H. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.2.152
Engineering Macrophages for Cell-Based Therapies
Lee, S. (2017) · eScholarship (California Digital Library)
Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma
de Larrea, C. F., Mailankody, S., Landgren, O., & Smith, E. L. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.72
Cancer immunotherapy: Adoptive cell therapies, cytokine-related toxicities, and the kidneys
Edeani, A. (2019) · Journal of Onco-Nephrology · doi:10.1177/2399369319863433
Liu, D., Peng, K., Huo, L., et al. (2018) · PubMed · doi:10.3760/cma.j.issn.0253-2727.2018.11.017
Resistance to Chimeric Antigen Receptor T-Cell Therapy
Xavier, A. C., & Costa, L. J. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-24424-8_9
T Cell Receptor Engineered T Cell Therapy in Oncology
Binder, G. K., & Amado, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00013-3 · Cited by 1
An update on options of therapy for aggressive mantle cell lymphoma
Ruan, J., Yamshon, S., van Besien, K., & Martin, P. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1755860 · Cited by 1
Wang, S. Y., Cao, J., & Xu, K. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.05.017
“[12] Turtle CJ, Hanafi LA, Berger C, et al.”
BackgroundGeorge, P. (2020) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17148182.v1
Guerrouahen, B. S., Elnaggar, M., Al-Mohannadi, A., Kizhakayil, D., Bonini, C., Benjamin, R., Brentjens, R. J., Buchholz, C. J., Casorati, G., Ferrone, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589381
Expanding the Toolbox of Adoptive Cell Immunotherapy
Hossain, N. M., & Stiff, P. J. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00295
Suivi immunologique des traitements par cellules CAR-T
Pescarmona, R., Bulteau, C., & Garnier, L. (2021) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(21)00105-2
The Development and Management of Treatment with Chimeric Antigen Receptor T Cell (CAR T)
Annesley, C., & Gardner, R. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-85147-7_15
Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma
Ebadi, M., Sadeghi, M. A., Reddy, N. M., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_7
Louie, R. H. Y., Cai, C., Singh, M., Deveson, I. W., Ferguson, J. M., Amos, T. G., McGuire, H. M., Samir, J., Gowrishankar, K., Adikari, T. N., et al. (2022) · medRxiv · doi:10.1101/2022.03.29.22273013 · Cited by 1
Ilić, D., & Trento, C. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0149
Human Vaccines & Immunotherapeutics: News
(2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1253965
Beauvais, D., Castilla‐Llorente, C., Diral, E., Sîrvent, A., Vandewiele, A., Baruchel, A., Yakoub‐Agha, I., & Yakouben, K. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.04.017
Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers
Wudhikarn, K., Tomás, A. A., Murata, K., & Perales, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824302-2.00012-6
Yoon, D. H., Koh, Y., Jung, M.-Y., Kwak, J.-E., Shin, E., Hwang, Y. K., & Kim, W. S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4099415
Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma
Sun, T., Zhou, M., & Huang, L. (2022) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0001
CAR-T Therapy: A Promising Cancer Treatment
Fang, Y., Liu, B., & Song, W. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v8i.1116
CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far
Greinix, H. T. (2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00830-9
Chen, S. Y., Chen, W., Wan, X., Du, X., Luo, C., Li, X., & Zhang, X. H. (2022) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2022.06.009
“[10] Turtle CJ, Hanafi LA, Berger C, et al.”
BackgroundYeung, S. J., & Escalante, C. P. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm141.pub2
T Cell Immunotherapy of Cancer
Palomba, M. L., Park, J. H., & Brentjens, R. J. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm067.pub3
Exploring the mechanisms of CD19 CAR T-cell failure and salvage strategies in B-cell lymphoma
Yang, F., Liu, R., & Hu, K. (2022) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0004 · Cited by 1
“Several studies have shown that the use of an intensive lymphodepletion regimen increases the expansion and persistence of initial CAR T-cells [83].”
BackgroundLymphodepletion and cellular immunotherapy
Yuan, Y., Deshpande, S., Rand, J. G., & Fong, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00009-4
Luan, R., & Deng, B. (2023) · Hematology and Oncology Discovery · doi:10.15212/hod-2022-0009
Gulbis, A. M., & Wallis, W. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00010-3
Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies
Cherng, H.-J. J., McGee, K., Hawkins, M., & Westin, J. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00009-7
Mechanisms and Clinical Features of Relapse and/or Refractory to CAR T-cell Therapy
Goto, H. (2023) · Japanese Journal of Transplantation and Cellular Therapy · doi:10.7889/tct-23-017
Zukunft der Stammzelltransplantation und neue zelluläre Therapien
Hudecek, M., Bornhäuser, M., & Schmitt, M. W. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_33-1
Hämatologische und onkologische Notfälle
Atta, J., Ajib, S. A., & Froh, S. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54675-4_107-2
Mariani, C., Borgonovo, F., Gerbi, M., Rizzardini, G., & Capetti, A. F. (2024) · AIDS Care · doi:10.1080/09540121.2023.2298768 · Cited by 1
“In non-Hodgkin ’ s lymphoma, the most frequent malignancy among PLWH, both CD4 + and CD8+ T-cells are low and the CD4/CD8 ratio is variable but generally preserved (Turtle et al., 2016).”
The Science of CAR ‐T Cell Technology
Godby, R. C., Bock, A. M., Kenderian, S. S., & Lin, Y. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch20
Additional file 1 of Strategies to enhance CAR-T persistence
Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Figshare · doi:10.6084/m9.figshare.21622536
Cellular Therapies for Cancer: Chimeric Antigen Receptor T Cells (CAR-T)
Godby, R. C., Niu, A., & Paludo, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-59475-5_5
Hämatologische und onkologische Notfälle
Atta, J., Ajib, S. A., & Froh, S. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-68699-7_107
Neuropsychological issues related to immunotherapy
Youssef, G., & Lee, E. Q. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15663-2.00026-2
Allograft persistence: The next frontier for allogeneic γδ T cell therapy
Fowler, D. W., & Fisher, J. P. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21766-1.00001-1
Combination of CAR-T cell therapies with conventional anti-cancer therapies
Escobar, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00030-8
The role of cellular persistence in CAR T cell therapy
Menkhoff, V. D., Bernhard, S., Michaelides, S., Stock, S., & Kobold, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00029-1
Considerations for nonclinical studies conducted to support the development of cellular therapies
Bolt, M. W., & Narayanan, P. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00011-0
CAR T in Childhood Acute Lymphoblastic Leukemia
Calkoen, F., & Buechner, J. (2024) · Pediatric oncology · doi:10.1007/978-3-031-71180-0_14
Arora, D., Aditi, A., Dinki, Taneja, Y., Chopra, B., & Dhingra, A. K. (2025) · Current Cancer Therapy Reviews · doi:10.2174/0115733947356323250227063508
Neurological Complications of Cancer Immunotherapy (CAR T-Cells)
Batra, A., Eckhardt, C. A., Rubin, D. B., & Vaitkevicius, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00295-5
Preconditioning Matters: Enhancing or Impairing Antitumor Immunity with DC VaccinesPreprint
Kwon, E., Namen, S. L., Willoughby, C. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.02.651990
Wang, K., Li, J., Yu, Z., Dong, L., Jiang, J.-T., Guo, Z., Wang, L., Zhang, H., Xu, L., & Zhang, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5348268
Yi, J., Qiao, Y., Xiong, Z., Feng, J., Zouxu, X., Zeyu, S., & Wang, X. (2025) · Journal of Cancer · doi:10.7150/jca.115507
Kwon, E., Namen, S. L., Willoughby, C. J., Kang, S., Pandey, G., Kim, A. B., & DeSelm, C. J. (2025) · Life · doi:10.3390/life15091402
Targeting PD-1 + T cells with chimeric antigen receptors to reduce the HIV reservoir
Ermellino, L., Banga, R., Georgakis, S., Kadzioch, N. P., Procopio, F., Alcaraz-Serna, A., Alfageme-Abello, O., Porret, R., Cecchin, R., Orfanakis, M., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeb7602
“Considering that the success of CAR-T cell therapies relies on the fitness and synergic effect of CD4 + and CD8 + T cells ( 26 , 27 ) and that CD4 + T cells are susceptible to HIV infection, we first evaluated additional editing strategies conferring HIV resistance.”
Installation of dominant-negative mutations in FAS and TGFβR2 via base editing in primary T cells
Wick, B. J., Kluesner, M. G., Slipek, N. J., Skeate, J. G., Niemeyer, E. M., Webber, B. R., & Moriarity, B. S. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201063 · Cited by 3
Cheng, C., Zhang, L., Cao, J., Li, X., Wen, Y., Liu, K., & Zhao, T. (2025) · Life Medicine · doi:10.1093/lifemedi/lnaf035 · Cited by 1
Gioacchino, M. D., Pagana, A., Mirabile, G., Valle, L. D., Stagno, F., Gangemi, S., & Allegra, A. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003226
Burchett, R., Morris, C. G., Ishak, M., Serniuck, N. J., Cummings, D. T., Baker, C. L., Marius, R. M., Kazdhan, N., Silvestri, C. M., Bell, J. C., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0070
Kellner, K. F. (2016) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.160390
Maloney, D. G., Kuruvilla, J. G., Liu, F. F., Kostić, A., Kim, Y., Bonner, A., Zhang, Y., Fox, C. P., & Cartron, G. (2021) · Figshare · doi:10.6084/m9.figshare.16584291
Li, C., Zhou, F., Wang, J., Chang, Q., Du, M., Luo, W., Zhang, Y., Xu, J., Tang, L., Jiang, H., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609288
Xu, J., Wang, B., Yu, S.-H., Chen, S.-J., Yang, S.-S., Liu, R., Chen, L.-J., Hou, J., Chen, Z., Zhao, W.-H., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25687360
Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16779661
Cartron, G., Fox, C. P., Liu, F. F., Kostic, A., Hasskarl, J., Li, D., Bonner, A., Zhang, Y., Maloney, D. G., & Kuruvilla, J. G. (2022) · Figshare · doi:10.6084/m9.figshare.19424825
Montagna, E., de Campos, N. S. P., Porto, V. A., da Silva, G. C. P., & Suarez, E. R. (2024) · Figshare · doi:10.6084/m9.figshare.26942547
From Bench to Bedside: Innovations and Challenges in CAR-T Cell Therapy Manufacturing and Regulation
Talukdar, J., Baishya, D., Karmakar, S., Ghosh, A., Seth, T., Kumar, U., & Ghatak, A. (2026) · Springer eBooks · doi:10.1007/978-981-95-3628-3_8 · Cited by 2
Clinical Success of CAR T Cells in Hematologic Cancers: Lessons from Leukemia and Lymphoma
Kumar, U., Tyagi, L., Sahu, B., Munjal, M., Rathi, G., Verma, S., Kumar, A., & Sohal, J. S. (2026) · Springer eBooks · doi:10.1007/978-981-95-3628-3_5
Personalized CAR T-Cell Therapy: Tailoring to Patient-Specific Tumors
Rai, A., Yadav, B., Pandit, K., Kumar, U., Charan, S., Sharma, S., Sharma, A., Saxena, P., & Pal, D. (2026) · Springer eBooks · doi:10.1007/978-981-95-3628-3_12
Ahmed, Z., Hamouche, W., Ahmad, S. O., Yu, J., Chowdhury, R. B., Gupta, S., Sullivan, D., Duffy, C., Ahmad, S., Anderson, K. C., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.01.015 · Cited by 1
Oner, A., Nooteboom, N., Oosting, L. T., Kosterink, J. G. W., Dekkers, B. G. J., van der Graaf, A. C., van Meerten, T., Krenning, G., Swart, D. H., Dennebos, R., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040414
Preclinical development of a T cell based gene therapy to treat IPEX syndrom
Delville, M. (2019) · theses.fr (ABES) · doi:10.70675/a98fdc5dz0036z4620z848ez66c60ea7bd96
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.